Understanding the Role of PBMs in the US Drug Pricing Debate
September 2023 – Targeting PBMs’ incentives and ability to negotiate lower prices with manufacturers could result in higher total drug spending.
The Promise of Digital Health for Home Dialysis Patients
May 2023 – Digital technology holds great promise for people with kidney failure, particularly those who are candidates for home dialysis.
Near-Term Expectations for Adalimumab Biosimilars in the United States
February 2023 – Biosimilar competition for Humira (adalimumab) has finally arrived, but a competitive market will take time to mature.
Biosimilar Market Opportunities in Ophthalmology
July 2022 – As the first opthalmology biosimilars enter the US market, there is potential to generate significant savings for the US healthcare system and incress access for patients.
Understanding Drug Rebates and Their Role in Promoting Competition
March 2022 – Drug rebates are not the drivers of high drug prices, but help lower health insurance premiums and drive competition among drug manufacturers.
How Patent Thickets Constrain the US Biosimilars Market and Domestic Manufacturing
May 2021 – In addition to blocking savings from biosimilars, patent thickets around reference biologics in the US create a barrier to the domestic manufacturing of biosimilars.
Potential Savings from Interchangeable Biosimilars in the Pharmacy Benefit
November 2020 – The exact level of savings arising from biosimilar interchangeability may be uncertain, but the potential for savings is significant.
The Cost of Brand Drug Product Hopping
September 2020 – Using a strategy known as product hopping, brand drug companies prevent generic competition, extend their monopoly prices, and keep costs high.
Negative Economic Impact of Restricting Drug Rebates in Medicare Part D
September 2020 – Restricting drug rebates in Medicare Part D without prompting an increase in federal spending, premiums, or out-of-pocket costs is infeasible.
Lessons for the United States from Europe’s Biosimilar Experience
June 2020 – In considering the European biosimilar experience, the United States should avoid certain market pitfalls but adopt some lessons to speed the development of the U.S. biosimilars market.
Biosimilar Savings Opportunities in the Medical Benefit: A Large-Employer Case Study
August 2019 – Biosimilars represent an important opportunity for employers and their health plan members to realize health care savings.
Gamesmanship and Other Barriers to Drug Competition
July 2019 – Brand drug companies use a wide array of tactics to delay generic competition for their products, resulting in substantial lost savings to the U.S. health care system.
Concerns Regarding the Proposed Rule to Restrict Drug Manufacturer Rebates in Medicare Part D and Medicaid MCOs
April 2019 – The proposed rule to restrict rebates is poorly conceived and holds the potential for serious negative consequences.
State Opioid Taxes: Economic & Health Policy Implications
January 2019 – A tax on prescription opioids would be ineffective at discouraging misuse and would impose a burden on the health care sector broadly.
Steps to Reducing Barriers to Biosimilars in the United States
September 2018 – Despite the existence of a regulatory pathway for biosimilars, barriers remain that hinder the development of a robust market for these cost-saving alternatives to biologic drugs.
Unrealized Savings from the Misuse of REMS and Non-REMS Barriers
September 2018 – Brand drug manufacturers’ practice of thwarting access to samples needed to develop generic drugs blocks an estimated $13.4 billion in generic savings—an increase of nearly 250 percent over four years.
The Crisis Facing Multiemployer Pension Plans
August 2018 – Millions of American workers’ retirements are at risk as their multiemployer pension plans head toward insolvency and the government agency meant to insure them is on the verge of bankruptcy.
REMS and Restricted Distribution Programs: An Estimate of the Market
June 2017 – In 2016, 74 drugs with total sales of $22.7 billion represented the segment of the drug market in which brand drug manufacturers could use REMS and other restricted access programs to block generic competition.
How the Next FDA Commissioner Can Address Drug Prices by Promoting Drug Competition
April 2017 – In the U.S. market, competition in the pharmaceutical sector is key to moderating drug prices, and the FDA plays an important role in fostering (or discouraging) this competition.
Employee Stock Ownership Plans as an Exit Strategy for Private Business Owners
March 2017 – Employee stock ownership plans offer business owners an exit strategy that preserves firm continuity, fosters employee commitment, and builds lasting economic value in a community.
Estimated Cost of FDA’s Proposed Generic Drug Labeling Rule: Updated for 2017–2024
July 2016 – The FDA’s Proposed Rule to permit generic drug manufacturers to change drug labels would increase generic spending by $5.6 billion in 2017, rising to $8.6 billion in 2024.
Payor Strategies to Promote Biosimilar Utilization
April 2016 – Carefully constructed physician incentives from public and private payors could boost biosimilar utilization, benefiting U.S. patients and the health care system as a whole.
Economic Benefits of Increased Home Dialysis Utilization and Innovation
March 2016 – If barriers to home dialysis were removed, the resulting increase in home dialysis utilization would both benefit patients and send strong signals to innovators to develop new technologies.
Understanding the True Causes of the U.S. Methamphetamine Problem
November 2015 – Fighting methamphetamine use in the United States by restricting access to cold and allergy medicines containing pseudoephedrine fails to address core underlying issues: continued demand for meth and an ample foreign supply.
American Association for Justice Misses on “The True Costs of Generic Drug Regulation”
April 2015 – An American Association for Justice report makes both unfounded criticisms of an MGA analysis and false assertions about the impact of the FDA Proposed Rule on generic drug labeling.
The Economic Viability of a U.S. Biosimilars Industry
February 2015 – Because of the expected regulatory framework and economic conditions, a robust U.S. biosimilars market for a broad spectrum of biologic products is unlikely, but biosimilar entry for blockbuster biologic products is viable.
Considerations of the FDA’s Impact on Competition in the Drug Industry
November 2014 – The FDA, within its core mission of ensuring the safety and efficacy of drugs, affects competition in the pharmaceutical industry in important ways.
Obesity in the Medicare Population: Opportunities for Cost Savings
October 2014 – The high rates of obesity among Medicare beneficiaries and the high cost of providing medical care to obese individuals create an enormous financial burden on the federal government.
Health and Economic Benefits of Weight Loss among Obese U.S. Adults
August 2014 – There is substantial potential savings, nationally and for the Medicare population, from preventing the development of five comorbidities by reducing obesity rates by 10 percent.
Lost Prescription Drug Savings from Use of REMS Programs to Delay Generic Market Entry
July 2014 – If brand drug manufacturers stopped misusing restricted distribution to keep drug samples from generic manufacturers, $5.4 billion in annual drug spending could be saved.
Budgetary Impact of Obesity in the United States
May 2014 – The prevalence of obesity nationwide and in Medicare, in particular, has a substantial federal budgetary impact, but there is evidence that reducing obesity lowers health care spending.
Comparing Economic Impact Estimates of “Reverse Payment” Settlements
February 2014 – Economic studies of “reverse payment” settlements have reached contradictory conclusions about the effect of this type of settlement on consumers, indicating that broad research provides little evidence of the appropriateness of any given settlement.
FDA’s Proposed Generic Drug Labeling Rule: An Economic Assessment
February 2014 – The FDA’s Proposed Rule to allow generic drug makers to make changes to product labels would drastically alter the legal landscape and increase spending on generics by $4 billion per year.
The Long-Term Returns of Obesity Prevention Policies
April 2013 – Obesity prevention policies need longer-term budget impact analyses than the typical 10-year estimates from the Congressional Budget Office.
Macroeconomic Impact of S ESOPs on the U.S. Economy
April 2013 – S corporations that sponsor employee stock ownership plans have a positive impact that benefits not only employee-owners, but also the broader economy.
An Analysis of the Economic Impact of Requiring Prescriptions for Pseudoephedrine Products
March 2013 – Combating methamphetamine by requiring prescriptions for pseudoephedrine medicines would force high social and economic costs on consumers.
An Analysis of the Benefits S ESOPs Provide the U.S. Economy and Workforce
July 2012 – Employee stock ownership plans have been shown to facilitate firm performance and job stability because they foster loyalty to the company among employees.
Proper Duration of Data Exclusivity for Generic Biologics: A Critique
November 2008 – With a regulatory pathway for biosimilars on the horizon, what is the appropriate duration of data exclusivity for innovator biologic drugs?
1350 Connecticut Avenue NW
Washington, DC 20036